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Khalid.Hussain@ucl.ac.ukAbstractBackground: Neonatal diabetes mellitus (NDM) is a rare form of monogenic diabetes and usually presents in the first
6 months of life. We aimed to describe the clinical characteristics and molecular genetics of a large Turkish cohort of NDM
patients from a single centre and estimate an annual incidence rate of NDM in South-Eastern Anatolian region of Turkey.
Design and methods: NDM patients presenting to Diyarbakir Children State Hospital between 2010 and 2013, and patients
under follow-up with presumed type 1 diabetes mellitus, with onset before 6 months of age were recruited. Molecular
genetic analysis was performed.
Results: Twenty-two patients (59% males) were diagnosed with NDM (TNDM-5; PNDM-17). Molecular genetic analysis
identified a mutation in 20 (95%) patients who had undergone a mutation analysis. In transient neonatal diabetes (TNDM)
patients, the genetic cause included chromosome 6q24 abnormalities (nZ3), ABCC8 (nZ1) and homozygous INS (nZ1).
In permanent neonatal diabetes (PNDM) patients, homozygous GCK (nZ6), EIF2AK3 (nZ3), PTF1A (nZ3), and INS (nZ1)
and heterozygous KCNJ11 (nZ2) mutations were identified. Pancreatic exocrine dysfunction was observed in patients with
mutations in the distal PTF1A enhancer. Both patients with a KCNJ11 mutation responded to oral sulphonylurea. A variable
phenotype was associated with the homozygous c.-331COA INS mutation, which was identified in both a PNDM and
TNDM patient. The annual incidence of PNDM in South-East Anatolian region of Turkey was one in 48 000 live births.
Conclusions: Homozygous mutations inGCK, EIF2AK3 and the distal enhancer region of PTF1Awere the commonest causes of
NDM in our cohort. The high rate of detection of a mutation likely reflects the contribution of new genetic techniques
(targeted next-generation sequencing) and increased consanguinity within our cohort.ice
.0 UEuropean Journal of
Endocrinology
(2015) 172, 697–705nsed under a Creative Commons
nported License.
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172 :6 698IntroductionNeonatal diabetes mellitus (NDM) is a rare form of
monogenic diabetes which presents in the first 6 months
of life (1). There are two main clinical subtypes of NDM:
permanent neonatal diabetes (PNDM) and the remitting
and frequently relapsing, transient neonatal diabetes
(TNDM) (2, 3). The underlying genetic defect in TNDM
can be ascertained in more than 90% cases. The majority
of cases of TNDM are linked to an imprinted region on
chromosome 6q24, the abnormality either being paternal
uniparental disomy, paternal duplication or defective
methylation of the maternal allele (4). The latter can
sometimes be due to biallelic mutations in ZFP57, a gene
involved in the regulation of DNA methylation (5).
Heterozygous mutations in genes encoding the KIR6.2
and SUR1 subunits of the pancreatic ATP-sensitive
potassium (KATP) channels (KCNJ11 and ABCC8) are
common causes of TNDM (6).
PNDM is genetically heterogeneous with mutations in
20 different genes described to date: KCNJ11, ABCC8,
FOXP3, GCK, PDX1, PTF1A, EIF2AK3, SLC2A2, GATA6,
SLC19A2, WFS1, NEUROD1, NEUROG3, RFX6, WFS1,
NKX2-2, MNX1, IER3IP1, INS and GLIS3 (1, 7). Hetero-
zygous mutations in the KCNJ11, ABCC8 and INS gene are
the most common causes of PNDM. However, in popu-
lations with a high degree of consanguinity, rare genetic
causes of PNDM such as homozygous mutations in
EIF2AK3, INS andGCK account for the majority of cases (8).
The incidence of NDM in different countries has been
calculated from the referral rate of new cases to the
diagnostic laboratory or referral endocrine centres. Thus
reported incidences are quite variable (one in 21 196 to
one in 215 417) not only depending on the calculation
method but also the population characteristics (e.g.
prevalence of consanguinity) (9, 10, 11). In general, the
incidence in western countries is lower than the eastern
countries with a high prevalence of consanguinity.
Turkey, particularly South-Eastern Anatolian region, is
an area with a high prevalence (O40%) of consanguineous
marriage (12).
To the best of our knowledge, the regional and
nationwide annual incidence of NDM has not been
reported from Turkey. We describe the clinical character-
istics, molecular genetics and long-term follow-up of a
large Turkish cohort of NDM patients from a single
paediatric endocrine centre. We also estimate the inci-
dence of NDM in South-Eastern Anatolian region of
Turkey based on referrals to a regional paediatric endo-
crine centre.www.eje-online.orgSubjects and methods
Patients
Patients referred/presenting with NDM to the paediatric
endocrine department at Diyarbakir Children State
Hospital, Turkey between January 2010 and December
2013 were phenotyped in detail. The paediatric endocrin-
ology department at Diyarbakir Children State Hospital
is the only paediatric endocrine centre in Diyarbakir and
also receives NDM referrals from four neighbouring cities
(Siirt, Sirnak, Mardin and Batman) in the South-Eastern
Anatolian region.
NDM was defined as onset of diabetes mellitus
diagnosed before 6 months of age. Details of clinical
presentation, birth and family history, clinical phenotype,
biochemical data, pancreatic imaging and management
were collected using a standardised proforma.
Molecular genetic analysis was undertaken as
described below. In addition, genetic analysis was under-
taken on patients with presumed type 1 diabetes mellitus
under follow-up where the clinical phenotype was
consistent with monogenic diabetes.Incidence of NDM
The annual incidence of NDM was calculated for the
South-Eastern Anatolian region of Turkey between 2010
and 2013 inclusive, based on referral rates of NDM to the
tertiary paediatric endocrine centre in Diyarbakir. The
annual live birth rate data for this region was supplied by
Turkish Statistical Institute (TSI; http://tuikapp.tuik.gov.
tr/demografiapp/dogum.zul).Genetic analysis
Genomic DNA was extracted from peripheral leukocytes
of 19 patients using standard procedures, and the coding
regions and intron/exon boundaries of the ABCC8,
KCNJ11, INS and EIF2AK3 genes were amplified by PCR
(primers available on request). The amplicons were
sequenced using the Big Dye Terminator Cycler Sequen-
cing Kit v3.1 (Applied Biosystems) according to manufac-
turer’s instructions, and reactions were analysed on an
ABI 3730 Capillary sequencer (Applied Biosystems). The
sequences were compared with the reference sequences
(NM_000525.3, NM_000352.3 (U63421 and L78208),
NM_000207.2 and AF110146.1) using Mutation Surveyor
v3.24 Software (SoftGenetics, State College, PA, USA).
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172 :6 699For one patient, Sanger sequencing of the coding
regions of GCK (NM_000162.3) was undertaken. This was
prompted by the presence of mild-fasting hyperglycaemia
in both parents. In a second patient with pancreatic
exocrine insufficiency, sequence analysis of a distal PTF1A
regulatory enhancer region was performed by methods
described previously (13).
All 20 known neonatal diabetes genes were sub-
sequently screened on the Illumina HiSeq2000 targeted
next-generation sequencing platform in six patients where
Sanger sequencing, or methylation analysis, had not
identified a causative mutation. Details of the method-
ology have been reported previously (7).
Chromosome 6q24 methylation analysis was
performed on three patients with TNDM, in whom
ABCC8, KCNJ11, INS and EIF2AK3 mutations had been
excluded. Methylation-specific PCR was used to detect
hypomethylation of the 6q24 locus, followed by micro-
satellite analysis to discriminate uniparental disomy of
chromosome 6 (UPD6pat) from isolated hypomethylation
at 6q24, as described (14). The samples with 6q24
hypomethylation but not UPD6pat were tested for
hypomethylation at other imprinted loci and for ZFP57
mutations, as described (5).
The study was performed according to the principles
of the Declaration of Helsinki with written informed
consent given by the patients’ parents.Table 1 Comparison of clinical characteristics for patients with
TNDM and PNDM.
TNDM (nZ5) PNDM (nZ17) P
Age at presentation
(weeks)
1.4G0.9 6.2G5.5 0.005Statistical analyses
Statistical analysis was performed using IBM SPSS 21.0 for
Windows statistical software. Shappiro–Wilk test was used
to test the normality of distribution of data. The ratios
were compared using c2 test (or Fisher’s exact test). The
means were compared using ‘independent sample t-test’
in normally distributed data and medians using Mann–
Whitney U test for non-normally distributed data. Data
were expressed as median (interquartile range) or
meanGS.D. (range). A P value %0.05 was considered to
be statistically significant.
Gestational age (weeks) 38.8G2.2 38.2G2.7 0.499
Birth weight (g) 2388G526 2213G626 0.596
Plasma glucose (mmol/l) 31.1G9.4 28.3G10.6 0.884
C peptide (pmol/l) 0.7G0.8 0.3G0.3 0.690
Serum insulin (mU/l) 5.2G1.5 4.2G3.2 0.345
Female/male 5/0 4/13 0.006
DKA at presentation
(n, %)
1/4 (25) 2/5 (40) 0.166
Monogenic diabetes in FH
(n, %)
2/5 (40) 10/14 (71) 0.126
Consanguinity in FH, n (%) 5/5 (100) 12/14 (86) 0.544
DKA, diabetic ketoacidosis; FH, family history.Results
Presenting characteristics
Twenty-two patients were diagnosed with NDM. Seven-
teen patients were born between January 2010 and
December 2013. Five patients were born before January
2010 but were not tested for mutations at the time of
diagnosis of NDM. Three of them had been misdiagnosedas type 1 diabetes mellitus, whereas two died in early
infancy.
NDM resolved in five patients (TNDM), whereas 15
patients had PNDM. Two patients died in early infancy
due to unrelated illnesses and hence could not be clearly
classified as TNDM or PNDM. However, due to a strong
indication of GCK-NDM, we classified these patients into
the PNDM group. Comparison of the two subtypes
revealed significant difference in the age at presentation
of diabetes, with TNDM patients presenting earlier than
PNDM patients (Table 1). Incidentally, all TNDM patients
in our cohort were females, whereas for all types of NDM,
the male-to-female ratio was 13:9.
Patients with EIF2AK3 and KATP channel mutations
were appropriate for gestational age (birth weight between
K2 S.D. and C2 S.D.), whereas patients with mutations in
GCK, PTF1A, INS and 6q24 methylation abnormality were
small for gestational age (birth weight!K2 S.D.) (Table 2).Annual incidence of NDM
According to TSI, the total number of live births in the
five cities (Diyarbakir, Siirt, Sirnak, Mardin and Batman) in
the South-Eastern Anatolian region of Turkey between
2010 and 2013 was 387 857. In our cohort of 22 NDM
patients, 13 patients (five TNDM and eight PNDM) were
born during this period across these five cities. These
figures suggest that the overall annual incidence of NDM
(and PNDM) during this period in the South-Eastern
Anatolian region of Turkey was at least one in 30 000
(one in 48 000) live births.www.eje-online.org
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172 :6 701Mutation analysis
The underlying genetic cause for NDM was identified in
20/21 (95%) patients by undergoing a mutation anlysis.
Chromosome 6q24 abnormalities, heterozygous ABCC8
and homozygous INS mutations were identified in three,
one and one patients respectively (Fig. 1). Two patients
with chromosome 6q24 methylation abnormalities had
a homozygous mutation in ZFP57 (p.Q322RfsX13 and
p.R228C) and one patient had paternal uniparental
isodisomy (UPD) of chromosome 6. The p.Q322RfsX13
(c.964delC) frameshift mutation is a single-base deletion
which results in the introduction of a premature termin-
ation codon. The p.R228C (c.682COT) mutation is a
missense mutation which is predicted to change the
conformation of a cys-his zinc finger 3.
The genetic cause of diabetes was identified in 15 of
the 17 PNDM patients. Nine different mutations in five
genes (GCK, EIF2AK3, PTF1A, KCNJ11 and INS) were
identified (Fig. 1). Two different homozygous GCK
mutations (p.K169R (c.506AOG) and p.C220R (c.658TOC))
were identified in four patients, two of whom were
siblings. A further two NDM patients who died in early
infancy of unrelated illnesses, siblings of patient 2, are
likely to have had GCK NDM (although not formally
tested) as both parents were heterozygous for the p.K169R
GCK mutation. Both mutations were novel at the time of
diagnosis, and affect residues which are highly conserved
across species. A different mutation at the same amino acid
residue has been reported previously (15).
Three different homozygous EIF2AK3 mutations were
identified in three patients, one of which, p.W521X
(c.1562GOA), has been reported previously (8, 16). The
remaining two mutations were novel (c.1884-1GOC and
p.Q333X (c.997COT)).
Two different homozygous mutations (chr10:
g.23508437 and chr10:g.23508365) in the distal enhancer
region of PTF1A (w25 kb downstream from PTF1A) were
identified in three patients. Both mutations have
been reported previously in patients with pancreatic
hypoplasia (13).
A previously reported heterozygous KCNJ11 mutation
(p.R201H, c.602GOA) was identified in two unrelated
patients (17). One patient had a previously reported
homozygous INS promoter mutation (c.-331COA) which
is predicted to disrupt a transcriptional regulatory site
resulting in decreased insulin transcription (18).
No mutation was identified in two patients, one
patient had been tested by targeted next-generationwww.eje-online.org
TNDM (n=5)
INS
(1)
UPDPat6
(1)
ZPF57
(2)
EIF2AK3
(3)
GCK
(6)
NA
(1)
NM
(1)
KCJN11
(2)
INS (1)
PTF1A
(3)
ABCC8
(1)
PNDM (n=17)
Figure 1
Distribution of mutations detected in patients with TNDM and
PNDM (NA, not available; NM, no mutation).
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172 :6 702sequencing (7). There was inadequate DNA available for
testing for the remaining patient.Clinical details and genotype–phenotype relation
All six patients with a homozygous GCK mutation were
born to consanguineous families and the median age of
presentation with diabetes was 5 days (range 2–28 days).
One patient had been misdiagnosed as type 1 diabetes
mellitus and confirmation ofGCKNDM was done at a later
age rather than at initial presentation. Two siblings of this
patient were diagnosed with NDM, but died in early
infancy. It is presumed that they also had the identical
homozygous GCK mutation. All these patients are
currently on a relatively high dose of s.c. insulin
(1.5 U/kg per day). In a trial to switch s.c. insulin therapy
to sulphonylurea, none of these patients responded.
Coincidentally, one patient also had thalassemia major
and required regular blood transfusions.www.eje-online.orgThe three patients with Wolcott–Rallison syndrome
(WRS), due to homozygous EIF2AK3 mutations, were from
consanguineous families and they presented with diabetes
at a median age of 85 days (range 66–96 days). Over a mean
follow-up period of 2.5 years, episodic elevation of liver
enzymes and skeletal abnormalities were noticed in two
patients. Imaging revealed pancreatic hypoplasia in one
patient who died at the age of 3 years due to acute liver
failure (Table 2).
The three patients with mutations in distal enhancer
region of PTF1A presented with diabetes at a median age of
3 weeks (range 1–10 weeks). In addition to NDM, all three
patients displayed symptoms of pancreatic exocrine
insufficiency and pancreatic hypoplasia on imaging.
The two patients with KCNJ11 mutations presented
with diabetes between 1 and 3 months of age. One of these
patients had additional neurological features including
epilepsy and developmental delay, which developed after
acute presentation with diabetic ketoacidosis. This patient
was misdiagnosed as type 1 diabetes mellitus and the
confirmation of KCNJ11 NDM was done at the age of 6.2
years. An attempt was made to switch both patients to an
oral sulphonylurea therapy after the molecular genetics
diagnosis. Both patients responded well to glibenclamide
(0.5 and 1.5 mg/kg per day respectively) and insulin
therapy was successfully weaned.
The patient with an ABCC8 mutation presented at
18 days of age and the diabetes remitted at the age of
7 months. She is now 2.4 years of age and has a normal
blood glucose profile. Post remission, her HbA1c improved
from 7.1% (54 mmol/mol) to 5.2% (33 mmol/mol).
Both patients with the homozygous INS promoter
mutation presented with NDM within the first week of life.
The mean birth weight was 1650 g at 36 weeks gestational
age. One patient remitted at the age of 65 days, whereas
the second patient, 13 months at the time of writing, was
on insulin therapy.
All three patients with NDM due to chromosome 6q
methylation abnormalities presented within first week
of life. The mean birth weight was 2440 g at 40 weeks
gestational age. All three patients remitted before
5 months of age. One patient with TNDM due to paternal
UPD died due to unrelated illness. The remaining two
patients with a ZFP57 mutation, aged 1 and 3 years, are
still in remission. Apart from macroglossia in one patient,
no other additional features were observed.
For the two patients in whom the underlying genetic
cause could not be established, there is a strong family
history of diabetes mellitus in at least three generations for
one patient (proband, father, brother and grandfather).
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172 :6 703None of the other diabetic members from his family had
been diagnosed during the neonatal period. Mutation
analysis of all 20 known NDM genes did not identify a
mutation in this patient. In the second patient, who died
at the age of 2.5 years, apart from NDM there were
additional features of thiamine-responsive megaloblastic
anaemia, pancreatic exocrine insufficiency and neurode-
velopmental delay. No improvement in insulin require-
ment was noticed with thiamine replacement. DNA was
not available from this patient.Discussion
We describe the genetic aetiology and clinical manifes-
tations of NDM patients from a single, large paediatric
endocrine centre from South-Eastern Anatolian region of
Turkey. To the best of our knowledge, our centre’s cohort
of 22 NDM patients is the largest single centre cohort,
20 of whom have received a genetic diagnosis.
In our study, mutations in GCK, EIF2AK3 and a distal
enhancer region of PTF1A were the commonest cause
of NDM, accounting for 30, 15 and 15% of genetically
confirmed cases respectively. Although homozygous
inactivating mutations in GCK are a rare cause of PNDM,
isolated cases of GCK PNDM are frequently reported from
consanguineous pedigrees (19, 20, 21). However, a recent
study from Saudi Arabia, where there is a high degree of
consanguinity, did not identify a single case ofGCK PNDM
(22). Another study looked at the genetic aetiology of Arab
and British cohorts tested in Exeter Peninsula Medical
School Genetics Laboratory between years 2006 and 2011
and found GCK PNDM in only five out of 88 Arabic
patients (5.7%) and one out of 77 British patients (1.3%)
tested (23). To the best of our knowledge, there have not
been any previous large case-series from Turkey reporting
the genetic cause of NDM. From our results, it seems that
GCK PNDM is the commonest cause of NDM in South-
Eastern Anatolian region of Turkey and accounts for more
than one-quarter of NDM cases. This is the highest
proportion of GCK PNDM reported to date. Our patients
with homozygous GCK mutations did not respond to the
trial of sulphonylurea therapy. We also noticed higher
requirement of insulin (1.5–2 U/kg per day) to maintain
normoglycaemia in GCK PNDM as compared with other
NDM patients.
The incidence of TNDM caused by mutation of ZFP57
was also high in our cohort. A recent study of a global
cohort (nZ163) of TNDM reported 12 patients (7.5%) with
mutation in ZFP57 (24), of which ten had homozygous
mutations from consanguineous pedigrees and only twohad heterozygous mutations derived from unrelated
parents (Mackay 2014 unpublished data). In the cohort
presented here, two out of the three TNDM cases with
chromosome 6q24 methylation abnormalities, had ZFP57
mutations. It is apparent that the prevalence of ZFP57
mutations correlated with that of consanguinity; this
should be borne in mind when TNDM is suspected because
the recurrence risk in affected pedigrees is 25%.
WRS (EIF2AK3 mutations) has been reported as the
most common cause of PNDM in consanguineous families
(8). Pancreatic agenesis/hypoplasia, acute episodes of liver
dysfunction and skeletal dysplasia during follow-up are
major clinical characteristics of WRS that have significant
influence on prognosis (8, 16, 24). Episodes of liver
dysfunction, ranging from mild elevation of serum
transaminases to severe hepatic failure, can develop at
any time from diagnosis (8, 16, 24). In our series with a
high percentage of consanguineous families, WRS was
the second most common cause after GCK PNDM. In our
cohort, one patient with a normal pancreas on ultrasound
imaging developed a self-limiting mild elevation of
transaminases, alanine transaminase and aspartate trans-
aminase at presentation. The second patient with normal
pancreatic magnetic resonance imaging did not develop
any liver dysfunction. However, a skeletal dysplasia was
noticed at the age of 1.5 year, which worsened during
follow-up. The third patient had pancreatic hypoplasia on
ultrasound imaging, developed hepatic failure and skeletal
dysplasia at the age of 1 year and died at the age of 3 years
due to the second episode of hepatic failure.
In our series, three patients from consanguineous
pedigrees with clinical manifestations of PNDM and
pancreatic exocrine insufficiency and pancreatic
hypoplasia/agenesis were found to have mutations in the
recently identified distal enhancer region of PTF1A (13).
Our results suggest that mutations in this regulatory
region of PTF1A are a relatively common cause of PNDM
in consanguineous families. No additional clinical features
were present in these patients, consistent with the
reported clinical phenotype of isolated pancreatic agenesis
with distal enhancer PTF1A mutations (13).
Although mutations in the KCNJ11 and ABCC8 genes
are the commonest cause of PNDM in European and
Japanese populations, in our study they accounted for
12.5% cases only (9, 25, 26, 27). Similar findings were
reported in the case-series from Saudi Arabia with 17
PNDM patients, in whom no KCNJ11 or ABCC8 mutations
were identified (22). Both of our patients carrying the
p.R201H KCNJ11 mutation could be switched to oral
sulphonylurea with distinctly different doses ofwww.eje-online.org
E
u
ro
p
e
a
n
Jo
u
rn
a
l
o
f
E
n
d
o
cr
in
o
lo
g
y
Clinical Study H Demirbilek, V B Arya
and others
Neonatal diabetes mellitus
in Turkish children
172 :6 704glibenclamide. It is well recognised that not all KCNJ11
mutations respond to oral sulphonylurea therapy (28).
Although it seemed that one patient had DEND pheno-
type, on careful assessment developmental delay and
epilepsy in this particular patient are likely to be due to
neurological insult sustained during acute prolonged
period of diabetic ketoacidosis coma. No cases of DEND
have been reported in association with p.R201H KCNJ11
mutation in the literature.
Our results suggest that the estimated incidence of
NDM in South-Eastern Anatolian region of Turkey was
higher than those of western European countries with low
rates of consanguineous marriage, but similar to the
incidence reported from the Arabic countries with high
rates of consanguineous marriage (9, 10, 11, 22, 29). The
high rate of consanguinity in South-Eastern Anatolian
region of Turkey and in our cohort (89%) was consistent
with these results (12). However, since South-Eastern
Anatolian region has a higher rate of consanguineous
marriage compared with the other regions of Turkey, this
estimated incidence may not reflect the true incidence of
NDM for the whole Turkish population (12). To determine
the true incidence rate of NDM in Turkey, multicentre and
larger nationwide studies are required.Conclusions
We present the largest cohort of NDM from a single
paediatric endocrine centre. Mutations in GCK, EIF2AK3
and the distal enhancer region of PTF1A were the
commonest causes of NDM in our cohort. With the
utilisation of candidate gene sequencing and targeted
next-generation sequencing, the underlying genetic cause
could be established in 95% of our NDM patients who had
undergone a mutation analysis. The high incidence and
predominance of non-KATP channel mutations are likely
to reflect the increased rate of consanguinity within our
cohort. Special care to the rare genetic causes in the
molecular genetic analysis of NDM is clearly required in
patients from consanguineous pedigrees.Declaration of interest
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